Business Context and Reporting Period
Company: Cardo Medical, Inc. (Note: Input metadata referenced "Biocardia," but the filing text identifies the registrant as Cardo Medical, Inc.)
Reporting Period: Quarterly period ended June 30, 2009 (Form 10-Q).
Business Overview: An early-stage orthopedic medical device company specializing in reconstructive joint devices (knee, hip) and spinal surgical devices. The company operates two segments: Reconstructive Division and Spine Division. All sales are currently generated in the United States.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 | Three Months Ended June 30, 2009 |
|---|---|---|---|
| Net Sales | $878,000 | $521,000 | $446,000 |
| Gross Profit | $708,000 | $448,000 | $358,000 |
| Gross Margin | 80.6% | 86.0% | 80.3% |
| Net Loss | $(2,563,000) | $(2,287,000) | $(1,339,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.01) | $(0.02) | $(0.01) |
| Cash and Cash Equivalents (End of Period) | $3,250,000 | $4,192,000 | $3,250,000 |
| Net Cash Used in Operating Activities | $(2,207,000) | $(714,000) | N/A |
| Total Assets | $12,420,000 | $11,474,000 | $12,420,000 |
| Total Liabilities | $1,201,000 | $777,000 | $1,201,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 68.5% year-over-year for the six months ended June 30, 2009 ($878k vs. $521k). This was driven by wider acceptance of the Knee product and the launch of the Hip product in Q1 2009, which generated $200k in sales YTD.
- Margin Compression: Gross margin decreased from 86.0% to 80.6% YTD. Management attributes this to the introduction of Hip products, which carry lower margins than Knee products, and a slight decrease in Knee product margins.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses surged 127% YTD ($3.08M vs. $1.40M). Increases were due to higher labor costs ($1.25M increase), depreciation/amortization ($461k increase) related to new instrumentation and intangible assets, and expanded office space.
- R&D Volatility: R&D expenses dropped significantly to $206k YTD from $1.145M in the prior year. The 2008 figure included a one-time $938k charge for in-process R&D acquired in June 2008. Excluding this charge, R&D spending remained relatively consistent.
- Inventory Build-up: Inventory increased by $634k YTD, contributing to the cash burn in operating activities.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: The company explicitly states a "going concern" uncertainty. With $3.25 million in cash, management projects this will not meet working capital needs for the next 12 months. Continued operations depend on securing additional debt or equity financing.
- Capital Raise: On June 30, 2009, the company received $3.02 million in cash contributions for 8.69 million shares of common stock. These shares were recorded as "common stock issuable" and were expected to be issued in August 2009.
- Product Pipeline: The company anticipates launching a Total Knee product in mid-2010. The Spine Division remains in the market development phase.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2009, citing material weaknesses related to staffing and reporting of unusual transactions (e.g., the reverse merger).
- Risk Factors: Key risks include the need for additional funding, dependence on third-party reimbursement, reliance on single-source manufacturers, and the early-stage nature of the business with a history of losses.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the $3.02 million equity raise and whether additional financing has been secured to cover the projected 12-month cash shortfall.
- Revenue Concentration: Review customer concentration risks; two customers accounted for 45% and 29% of sales in Q2 2009, and three customers accounted for 73% of sales YTD.
- Internal Controls: Assess the remediation plan for the material weaknesses in internal controls over financial reporting.
- Product Mix Impact: Monitor the sales mix between Knee and Hip products to understand the trajectory of gross margins.
- Inventory Levels: Evaluate the $1.58 million inventory balance against sales velocity to ensure no obsolescence risks exist.